Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

313.25 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23
Open 313.25
Bid (Size) 308.85 (3)
Ask (Size) 317.00 (2)
Prev. Close 313.25
Today's Range 313.25 - 313.25
52wk Range 233.01 - 325.19
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
 
Via Benzinga
Alkermes Stock Sees Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily

Performance

YTD
+9.52%
+9.52%
1 Month
+8.99%
+8.99%
3 Month
+9.02%
+9.02%
6 Month
+10.01%
+10.01%
1 Year
+22.50%
+22.50%

More News

Read More
3 Small Financial Software Makers Showing Strong Chart Action
Via MarketBeat
Bullish News May Push Vertex Pharmaceuticals Above 52-Week High
Via MarketBeat
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Via Investor's Business Daily
How Is The Market Feeling About Vertex Pharmaceuticals?
Via Benzinga
10 Analysts Have This to Say About Vertex Pharmaceuticals
Via Benzinga
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Moderna?
Via The Motley Fool
Want $1 Million in Retirement? Buy and Hold These 5 Stocks
Via The Motley Fool
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Via InvestorPlace
Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend
Via The Motley Fool
This Is My Highest-Conviction Stock to Own in 2023 and Beyond
Via The Motley Fool
Got $3,000? 3 Growth Stocks to Double Up on Right Now
Via The Motley Fool
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
The Best Stocks to Invest $20,000 in Right Now
Via The Motley Fool
3 Monster Stocks to Buy Without Any Hesitation
Via The Motley Fool
3 Surefire Stocks That Can Thrive During a Recession
Via The Motley Fool
12-Stock Portfolio -- 25 Growth Stocks to Buy Now
Via The Motley Fool
Worried About the Banking Turmoil? These 3 Stocks Shouldn't Skip a Beat
Via The Motley Fool
3 Pharma Stocks That Could Benefit from Global Healthcare Trends
Via InvestorPlace
Exelixis Stock Generating Improved Relative Strength Rating
Via Investor's Business Daily
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.